Karen So

1.4k total citations
46 papers, 1.0k citations indexed

About

Karen So is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karen So has authored 46 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 21 papers in Oncology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karen So's work include PI3K/AKT/mTOR signaling in cancer (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Colorectal Cancer Treatments and Studies (9 papers). Karen So is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Colorectal Cancer Treatments and Studies (9 papers). Karen So collaborates with scholars based in United Kingdom, United States and France. Karen So's co-authors include Sharon O’Kane, Tracey Mason, James Bush, Mark W. J. Ferguson, Piyush Durani, Jeremy S. Bond, Anthony D. Metcalfe, Jonathan Duncan, Karthick Vishwanathan and Karen Thomas and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Karen So

46 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen So United Kingdom	16	341	331	295	215	174	46	1.0k
Toshihide Hara Japan	15	205 0.6×	69 0.2×	63 0.2×	178 0.8×	188 1.1×	37	995
Henrik J. Jürgensen Denmark	18	322 0.9×	290 0.9×	66 0.2×	136 0.6×	17 0.1×	25	1.1k
Takeya Adachi Japan	13	124 0.4×	169 0.5×	31 0.1×	117 0.5×	254 1.5×	45	1000
Donglin Luo China	17	599 1.8×	168 0.5×	88 0.3×	62 0.3×	27 0.2×	38	965
Le Qu China	20	884 2.6×	234 0.7×	43 0.1×	415 1.9×	108 0.6×	61	1.4k
Rashaud Senior United States	7	211 0.6×	137 0.4×	58 0.2×	183 0.9×	20 0.1×	11	1.1k
Howard R. Higley United States	12	220 0.6×	170 0.5×	35 0.1×	62 0.3×	152 0.9×	19	939
Anniina Färkkilä Finland	21	929 2.7×	648 2.0×	89 0.3×	120 0.6×	17 0.1×	51	1.7k
Mitsuru Kinjo Japan	17	257 0.8×	186 0.6×	21 0.1×	185 0.9×	51 0.3×	65	939

Countries citing papers authored by Karen So

Since Specialization

Citations

This map shows the geographic impact of Karen So's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen So with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen So more than expected).

Fields of papers citing papers by Karen So

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen So. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen So. The network helps show where Karen So may publish in the future.

Co-authorship network of co-authors of Karen So

This figure shows the co-authorship network connecting the top 25 collaborators of Karen So. A scholar is included among the top collaborators of Karen So based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen So. Karen So is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suenobu, Souichi, Keita Terashima, Masaharu Akiyama, et al.. (2023). Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study. Neuro-Oncology Advances. 5(1). vdad054–vdad054. 7 indexed citations

Ho, Alan L., Marek Dedecjus, Lori J. Wirth, et al.. (2022). Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). Journal of Clinical Oncology. 40(17). 1870–1878. 37 indexed citations

So, Karen, et al.. (2022). A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. Clinical Therapeutics. 44(4). 565–576. 1 indexed citations

Schalkwijk, Stein, Li Zhou, Lokesh Jain, et al.. (2021). Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemotherapy and Pharmacology. 88(2). 189–202. 10 indexed citations

Någård, Mats, Mei-Lin Ah-See, Karen So, et al.. (2020). Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 86(1). 97–108. 8 indexed citations

Grande, Enrique, R. Donald Harvey, Benoît You, et al.. (2019). Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. Journal of Pharmacology and Experimental Therapeutics. 369(2). 291–299. 15 indexed citations

Tomkinson, Helen, Eileen McBride, Paul Martin, et al.. (2017). Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects. Clinical Therapeutics. 39(11). 2260–2275.e1. 12 indexed citations

Elks, Cathy E., Paul Martin, David Carlile, et al.. (2017). Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European Journal of Clinical Pharmacology. 73(6). 717–726. 12 indexed citations

Dean, Emma, Nicola Steele, Hendrik‐Tobias Arkenau, et al.. (2016). SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Annals of Oncology. 27. vi439–vi439. 2 indexed citations

10.

Howes, Colin, et al.. (2016). Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects. Clinical Therapeutics. 38(11). 2447–2458. 24 indexed citations

11.

So, Karen, Paul Martin, Yifan Huang, et al.. (2016). Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. European Journal of Clinical Pharmacology. 73(2). 175–184. 23 indexed citations

12.

Dirix, Luc, Helen Swaisland, Henk M.W. Verheul, et al.. (2016). Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. Clinical Therapeutics. 38(10). 2286–2299. 47 indexed citations

13.

Swaisland, Helen, Ruth Plummer, Karen So, et al.. (2016). Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies. Cancer Chemotherapy and Pharmacology. 78(4). 775–784. 12 indexed citations

14.

Zhou, Diansong, Karen So, Nidal Al‐Huniti, et al.. (2016). Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Clinical Therapeutics. 38(12). 2555–2566. 3 indexed citations

15.

Plummer, Ruth, Helen Swaisland, Karin Leunen, et al.. (2015). Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 76(4). 723–729. 47 indexed citations

16.

Rolfo, Christian, Helen Swaisland, Karin Leunen, et al.. (2015). Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. Advances in Therapy. 32(6). 510–522. 40 indexed citations

17.

Hoffman, Steven J. & Karen So. (2015). Assessing 15 Proposals for Promoting Innovation and Access to Medicines Globally. Annals of Global Health. 80(6). 432–432. 6 indexed citations

18.

Jossinet, J., John Byrne, Julian Chantrey, et al.. (2010). Remote Wound Monitoring of Chronic Ulcers. IEEE Transactions on Information Technology in Biomedicine. 14(2). 371–377. 20 indexed citations

19.

Bush, Jim, Karen So, Tracey Mason, et al.. (2010). Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring. Dermatology Research and Practice. 2010(1). 14 indexed citations

20.

Ferguson, Mark W. J., Jonathan Duncan, Jeremy S. Bond, et al.. (2009). Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. The Lancet. 373(9671). 1264–1274. 215 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact